Dimitropoulos Konstantinos, Gravas Stavros
Department of Urology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.
Drug Des Devel Ther. 2015 Mar 19;9:1707-16. doi: 10.2147/DDDT.S53184. eCollection 2015.
Treatment of male lower urinary tract symptoms (LUTS) has traditionally focused on the management of benign prostatic obstruction, but the contribution of bladder dysfunction has been recently recognized. Therefore, it is well understood that LUTS have multifactorial etiology and often occur in clusters and not in isolation. Voiding LUTS are highly prevalent in men, but storage LUTS have been proved to be more bothersome. α1-Blockers are the most widely used pharmacologic agents for the treatment of symptoms relating to benign prostatic enlargement due to benign prostatic hyperplasia (BPH), while antimuscarinics are the drug class of choice for overactive bladder symptoms. A combination of the two drug classes would be a reasonable approach to treat men with both storage and voiding symptoms, and several short-term studies have proved the efficacy and safety of different combinations with an α1-blocker and an antimuscarinic. Following previous studies on the separate administration of solifenacin and tamsulosin, a fixed-dose combination tablet of tamsulosin oral controlled absorption system (OCAS) 0.4 mg and solifenacin succinate 6 mg has been recently introduced, and the current review evaluates the available data on the use of this fixed-dose combination in the treatment of LUTS in men with BPH.
男性下尿路症状（LUTS）的治疗传统上主要集中在良性前列腺梗阻的管理上，但膀胱功能障碍的作用最近已得到认可。因此，人们清楚地认识到，LUTS具有多因素病因，且往往成群出现而非孤立存在。排尿期LUTS在男性中非常普遍，但储尿期LUTS已被证明更令人困扰。α1阻滞剂是治疗因良性前列腺增生（BPH）导致的良性前列腺肿大相关症状最广泛使用的药物，而抗毒蕈碱药物是治疗膀胱过度活动症症状的首选药物类别。将这两类药物联合使用可能是治疗既有储尿期症状又有排尿期症状男性的合理方法，并且多项短期研究已证明不同的α1阻滞剂与抗毒蕈碱药物联合使用的有效性和安全性。继先前关于索利那新和坦索罗辛单独给药的研究之后，最近推出了一种坦索罗辛口服控释系统（OCAS）0.4毫克与琥珀酸索利那新6毫克的固定剂量复方片剂，本综述评估了关于使用这种固定剂量复方制剂治疗BPH男性LUTS的现有数据。
